AI assistant
FATE THERAPEUTICS INC — Director's Dealing 2022
Jun 6, 2022
34091_dirs_2022-06-06_102457a8-1a3d-444f-8faf-f6f34531ec1e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2022-06-03
Reporting Person: Agarwal Shefali (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-06-03 | Common Stock | S | 807 | $22.80 | Disposed | 1874 | Direct |
Footnotes
F1: Required number of shares sold by the reporting person to cover tax obligations in connection with the vesting of 2,681 shares of Common Stock underlying RSUs granted to the reporting person on June 2, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Represents the weighted average sale price of the shares sold from $22.53 to $22.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2.